Drug intelligence / Profile preview

UM-8930

Development stage: Unknown
Lead developer: Skye Bioscience
Modality: Small Molecules

Overview

UM-8930 is an experimental small-molecule prodrug asset originating from the University of Mississippi and licensed to Nemus Bioscience (now Skye Bioscience) for pharmaceutical development, but no detailed public information on its chemical structure, pharmacological target, mechanism of action, indication, or clinical development program has been disclosed. Available SEC filings describe UM-8930 only in the context of intellectual property and license agreements, indicating it is covered by “UM Know-How” and related patents, without specifying therapeutic area or biological activity.[9][11]

Beyond the preview

Go deeper on UM-8930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UM-8930.

Explore the full profile